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Abstract: Methadone is used for the treatment of opioid addiction and for treatment of chronic
pain. The safety of methadone has been called into question by data indicating a large increase in
the number of methadone-associated overdose deaths in recent years that has occurred in parallel
with a dramatic rise in the use of methadone for chronic pain. The American Pain Society and the College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society, commissioned an interdisciplinary expert panel to develop a clinical practice guideline on safer prescribing
of methadone for treatment of opioid addiction and chronic pain. As part of the guideline development process, the American Pain Society commissioned a systematic review of various aspects related
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to safety of methadone. After a review of the available evidence, the expert panel concluded that
measures can be taken to promote safer use of methadone. Specific recommendations include the
need to educate and counsel patients on methadone safety, use of electrocardiography to identify
persons at greater risk for methadone-associated arrhythmia, use of alternative opioids in patients
at high risk of complications related to corrected electrocardiographic QTc interval prolongation, careful dose initiation and titration of methadone, and diligent monitoring and follow-up. Although
these guidelines are based on a systematic review, the panel identified numerous research gaps,
most recommendations were based on low-quality evidence, and no recommendations were based
on high-quality evidence.
Perspective: This guideline, based on a systematic review of the evidence on methadone safety,
provides recommendations developed by a multidisciplinary expert panel. Safe use of methadone requires clinical skills and knowledge in use of methadone to mitigate potential risks, including serious
risks related to risk of overdose and cardiac arrhythmias.
ª 2014 by the American Pain Society
Key words: Clinical practice guideline, methadone, safety, chronic pain, opioid addiction.

Dear Reader,
The development of guidelines is a complex and costly
enterprise. Funding is increasingly reliant on providing
impact and outcome data. The American Pain Society requests your assistance in evaluating the impact of the
Methadone Safety Guideline. Please follow this link
(http://www.surveygizmo.com/s3/1548754/APS-Metha
done-Survey) to complete a brief questionnaire before
reading the guideline. The survey consists of 11
multiple-choice questions and should take no more
than a few minutes.
We also seek readers willing to take a follow-up survey (see instructions at the end of this survey). These
data will assist the APS in developing data on guideline
impact and thus assist us in securing and determining
allocation of funding in the future. We are offering a token incentive for your participation.
Thank you for your cooperation.
Clinical Practice Guidelines Committee
American Pain Society

M

ethadone is a synthetic opioid used for the
treatment of opioid addiction and for treatment of chronic pain.15,61 The safety of
methadone has been called into question by data
indicating a large increase in the number of
methadone-associated overdose deaths.38 This increase
appears largely related to the dramatic rise in the use
of methadone for chronic pain, though a small proportion of deaths occur in patients treated for opioid addiction.21,37,68,76,91,103 Methadone poisoning deaths in the
United States increased steadily from about 800 in 1999
to a high of about 5,500 in 2007; there was a decrease
to about 4,900 in 2008.101 The rate of increase in mortality has been substantially larger than for any other
opioid.32 About 1 of every 3 opioid-related deaths is
associated with methadone ingestion, a substantially
higher proportion than any other opioid.11 Although
this guideline focuses on methadone, clinicians should
also be aware of the overall rise in morbidity and mortality due to other prescription opioids.

The interpretation of data on methadone-associated
deaths is complicated by a number of factors, including
increased surveillance, differentiating prescribed versus
nonprescribed use of methadone, effects of other potential contributing factors (such as use of other medications
and substances), and uncertainty regarding the degree
to which increases in deaths are proportionate to
increased prescribing. Ascribing cause of methadoneassociated death is a particular challenge. In the vast majority of cases, it is not possible to determine whether the
death occurred as a result of respiratory depression
related to overdose or to other factors, such as
arrhythmia. Nonetheless, it is widely acknowledged
that the pharmacology of methadone may be associated
with unique safety concerns. This pharmacology includes
a long and variable half-life, potential interactions with
multiple medications, variability in equianalgesic dose
ratios depending on dose, and association with prolongation of the corrected electrocardiographic QT (QTc) interval, which may predispose patients to the ventricular
arrhythmia torsades de pointes.5,45,58,66,67,69,85,89 Data
from the Food and Drug Administration’s (FDA’s)
Adverse Event Reporting System indicate that since
2000, methadone was the second most commonly
suspected primary cause of drug-related arrhythmia, after dofetilide.51 The proportion of methadoneassociated deaths related to arrhythmia is likely to be
small relative to the proportion related to accidental
overdose, though reliable estimates are not available.
Three previous guidelines published between 2008 and
2011 addressed methadone safety, each focusing on prevention of cardiac arrhythmias due to the association between methadone and prolonged QTc interval seen on
electrocardiogram (ECG).60,70,92 Two of these guidelines
were not fully endorsed by a professional society or
government entity60,92; the third was endorsed by the
Substance Abuse and Mental Health Services
Administration.72 Although systematic literature reviews
were conducted for these guidelines, a limitation is that
none graded the strength of the recommendations or
the quality of the evidence supporting the recommendations. In addition, they did not address methadone safety
issues other than cardiac arrhythmias.
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The American Pain Society (APS) and the College on
Problems of Drug Dependence (CPDD), in collaboration
with the Heart Rhythm Society (HRS), commissioned an
interdisciplinary panel to develop a clinical practice guideline on safer prescribing of methadone for treatment of
opioid addiction and chronic pain. As part of the guideline
development process, APS commissioned a systematic review on various aspects related to safety of methadone.17

Methods
Panel Composition
The APS and CPDD convened a panel of 16 members
with expertise in pain, addiction medicine, cardiology,
primary care, nursing, palliative care, pharmacology,
adolescent medicine, obstetrics and gynecology, epidemiology, and social work to review the evidence and
formulate recommendations on methadone safety (see
Appendix 1 for list of panel members). Two cochairs
(R.A.C. and D.A.F.) were selected by the APS and CPDD
to lead the panel, which also included the APS Director
of Clinical Guidelines Development (R.C.). The HRS was
invited to join the guideline development process after
cochair and initial panel selection had taken place, and
it appointed 2 members with expertise in arrhythmia
(M.C.H. and D.M.) to the panel.

Target Audience and Scope
The intent of the Guideline is to provide, where
possible, evidence-based recommendations for use of
methadone in persons of all ages (including pregnant
women) for treatment of chronic pain in primary care
or specialty settings or for treatment of opioid addiction
in licensed opioid treatment programs. The target audience is all clinicians who prescribe methadone. Methadone is not approved by the FDA for use in acute or
postoperative pain, and its off-label use for these indications is outside the scope of this guideline, as is illicit use.

Funding and Conflicts of Interest
Funding for the Guideline was provided by the APS.
The Guideline was approved by APS and CPDD, but the
content of the Guideline is the responsibility of the authors and panel members. All panelists were required to
disclose conflicts of interest within the preceding 5 years
at all face-to-face meetings and prior to submission of the
Guideline for publication, and to recuse themselves from
votes if a conflict was present. Conflicts of interest of the
authors and panel members are listed in Appendix 1.

Evidence Review
This Guideline is informed by a systematic evidence review that addressed a variety of topics related
to methadone safety conducted at the Oregon
Evidence-based Practice Center and commissioned by
APS and CPDD.17 With the Oregon Evidence-based Practice Center, the panel developed the key questions,
scope, and inclusion criteria used to guide the evidence
review. Literature searches were conducted in multiple
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electronic databases from their start date through July
2012. An update search was performed in January 2014
for new studies on methadone-related overdose and
arrhythmia. Details about the methods used to conduct
the review, including complete search strategies, are
available in the full report.17 Investigators reviewed
3,746 abstracts from electronic databases, reference lists,
and suggestions from expert reviewers. Two systematic
reviews and 168 primary studies (not included in previously published systematic reviews) were included in
the evidence report.17

Grading of the Evidence and
Recommendations
The panel used methods adapted from the Grading of
Recommendations Assessment, Development, and Evaluation Working Group to rate the recommendations
included in this Guideline.40 Each recommendation
received a separate grade for the strength of the recommendation (strong or weak) and for the quality of evidence (high, moderate, or low) (Appendix 2). In
general, a strong recommendation is based on the
panel’s assessment that the potential benefits of
following the recommendation clearly outweigh potential harms and burdens, or that the potential harms
clearly outweigh potential benefits. Given the available
evidence, most clinicians and patients would choose to
follow a strong recommendation. A weak recommendation is based on the panel’s assessment that benefits of
following the recommendation outweigh potential
harms and burdens (or vice versa), but the balance of
benefits to harms or burdens is smaller or evidence is
weaker. Decisions to follow a weak recommendation
could vary depending on specific clinical circumstances
or patient preferences and values. For grading the quality of a body of evidence that supports a recommendation, we considered the type, number, size, and quality
of studies; strength of associations or effects; and consistency of results among studies.41 The quality of evidence
indicates the level of certainty in the recommendation
and the likelihood that future research could change recommendations. A recommendation based on lowquality evidence has a high probability of being affected
by new evidence, and a recommendation based on highquality evidence has a low probability. Strong recommendations based on low-quality evidence indicate
that until better evidence becomes available, the panel
determined that the benefits of following the recommended course of action clearly outweigh harms. In
some cases, recommendations based on low-quality
evidence are followed by ‘‘practice advice’’ with more
specific suggestions for implementing the recommendation in clinical practice, based on panel consensus.

Guideline Development Process
The Guideline panel met in person in May 2010 and July
2011. At the first meeting, the panel developed the scope
and key questions used to guide the systematic evidence
review. At the second meeting, the panel reviewed the results of the evidence review and drafted initial potential
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recommendation statements. Following the second
meeting, additional draft recommendation statements
were proposed. The panelists then participated in a multistage Delphi process, in which each draft recommendation
was ranked on clinical importance and usefulness, and
revised. At each stage of the Delphi process, the lowestranked recommendations were eliminated. A two-thirds
majority was required for a recommendation to be
approved. However, unanimous or near-unanimous
consensus was achieved for all recommendations. After
finalization of the recommendations, the Guideline was
written by various panel members and drafts distributed
to the panel for feedback and revisions. More than 20
external peer reviewers from multiple clinical and scientific
disciplines and professional societies were solicited for
additional comments. After another round of revisions
and panel approval, the Guideline was approved by the
APS Board of Directors on May 7, 2013, and by the CPDD
Board of Directors on November 5, 2013.
The APS intends to update its clinical practice guidelines regularly. This Guideline and the evidence report
used to develop it will be reviewed and updated by
2018, or earlier if critical new evidence becomes available.
The panel formulated the recommendations to be
generally applicable across age groups, though the great
bulk of evidence was in adult populations. Recommendations were also developed to be applicable to methadone prescribing for treatment of both opioid addiction
and chronic pain, unless otherwise noted.

Recommendations
Patient Assessment and Selection
 When considering initiation of methadone, the panel
recommends that clinicians perform an individualized
medical and behavioral risk evaluation to assess risks
and benefits of methadone, given methadone’s specific pharmacologic properties and adverse effect profile (strong recommendation, low-quality evidence).
Proper patient selection is critical when considering
the use of any opioid, whether for chronic pain or treatment of addiction.16 This requires a comprehensive
benefit-to-harm evaluation based on a thorough history, review of records, and physical examination.
Opioid therapy generally is considered the mainstay
in the treatment of chronic moderate or severe pain
associated with active cancer or at end of life. In
contrast, for other types of chronic noncancer pain,
opioids are usually considered after other reasonable
pain management strategies have proved ineffective.
In all populations, opioids should be considered only
in the context of information that weighs the potential
beneficial effects of prescribed opioids against risks,
including those related to their potential for abuse,
addiction, diversion, overdose, relapse (for patients
treated for addiction), and other adverse events. The
assessment should include evaluation of biomedical,
psychosocial, and cultural issues that may affect use
of and adherence to methadone treatment. An American Pain Society–American Academy of Pain Medicine
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(APS-AAPM) Guideline provides additional details on
patient assessment and selection when opioid therapy
is under consideration for chronic pain.16 This Guideline recommends that clinical findings or the results
of specific assessment tools be used to stratify patients
according to the assessed risk of substance abuse outcomes, and that this assessment be used in deciding
whether to proceed with a trial of an opioid.
Once a decision is made to undertake a trial of
long-term opioid therapy for pain, or to continue
treatment that has provided benefit, a second analysis
is needed to determine whether methadone may be
an appropriate analgesic. This assessment is informed
by many factors, as described below. When methadone is considered for the treatment of opioid addiction, other factors are considered, such as the level of
physical dependence, presence of a structured environment, involvement in ongoing treatment and recovery activities, patient stability, prior experience
with addiction treatments, concurrently prescribed
medications, other drug abuse, current comorbidities,
and patient preferences for opioid therapy. When
treating patients with chronic pain, given the availability of alternatives, clinicians should always consider
whether another opioid may be a more appropriate
therapy, when an opioid is indicated.
The necessity for additional evaluation concerning
the specific use of methadone for pain and addiction
is based on unique pharmacologic properties that
can affect determinations of benefits relative to risks,
which include a long and variable half-life, numerous
drug-drug interactions (including alcohol), and effects
on the electrocardiographic QTc interval and respiratory depression. For example, a patient otherwise assessed as an appropriate potential candidate for
opioid treatment who is taking a medication with potential methadone interactions or has risk factors for
QTc interval prolongation or known QTc interval prolongation may be more appropriately treated with
an alternative opioid (see below).45,58,67,69

Patient Education and Counseling
 The panel recommends that clinicians educate and
counsel patients prior to the first prescription of methadone about the indications for treatment and goals
of therapy, availability of alternative therapies, and
specific plans for monitoring therapy, adjusting doses,
potential adverse effects associated with methadone,
and methods for reducing the risk of potential adverse
effects and managing them (strong recommendation,
low-quality evidence).
As with any other opioid, clinicians should counsel
patients about potential risks and benefits before initiating a trial of methadone. During treatment, clinicians should periodically review risks and benefits of
therapy. An APS-AAPM guideline on opioid therapy
for chronic pain provides additional details regarding
suggested elements of patient education in the setting
of pain management, as well as a sample informed
consent form.16

Chou et al
In addition to common opioid-related adverse
events, clinicians should discuss specific risks associated
with methadone and factors that may be associated
with overdose.32,38 These include methadone’s long
and variable half-life, the potential association between use of methadone and QTc interval prolongation
and cardiac arrhythmia, and the potential for drugdrug interactions.45,58,67,69 Patients should be
specifically informed about methods for mitigating
risks, including the importance of taking methadone
as prescribed and adherence with recommended
follow-up and monitoring. Patients seen in clinical settings other than the one in which methadone is prescribed should be informed that their receipt of
methadone will not be apparent if it is not linked to
the electronic medical records of that setting or to state
prescription-monitoring programs, and they should be
educated about the importance of disclosing its use. Patients, as well as caregivers and family members who are
actively engaged in the patient’s care, should be notified about the risks of respiratory depression and instructed to withhold additional doses of methadone
and contact the prescribing or dispensing entity if signs
of respiratory depression or somnolence are present.
Patients should be instructed to never share methadone
and to store methadone in a safe place, such as a locked
cabinet or box if necessary, to safeguard against theft.
An opioid management plan describes how methadone will be prescribed and monitored in an individual
patient. It is distinct from the informed consent process, which refers to a discussion of the potential
benefit and harms of a therapy. As for all opioids, the
management plan when prescribing methadone for
treatment of chronic pain may include elements intended to help monitor and verify use. These may
include the stipulation that methadone is obtained
from one prescriber or facility, prescriptions are filled
at one designated pharmacy, drug screening is performed periodically, office visits are required at a specified minimum interval, pill counts are conducted at
office visits, and prescription size is limited (eg, weekly
or biweekly instead of monthly amounts in higher-risk
patients).16 To ensure that key messages are conveyed
to patients consistently, prescribers should consider
the use of a written methadone management plan.16
This plan may also include enumeration of behaviors
that may result in discontinuation of methadone.

Baseline Electrocardiograms
 The panel recommends that clinicians obtain an ECG
prior to initiation of methadone in patients with risk
factors for QTc interval prolongation, any prior ECG
demonstrating a QTc >450 ms, or a history suggestive
of prior ventricular arrhythmia. An ECG within the
past 3 months with a QTc <450 ms in patients without
new risk factors for QTc interval prolongation can be
used for the baseline study (strong recommendation,
low-quality evidence).
 The panel recommends that clinicians consider obtaining an ECG prior to initiation of methadone in patients
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not known to be at higher risk for QTc interval prolongation; an ECG within the past year with a QTc <450 ms
in patients without new risk factors for QTc interval prolongation can be used for the baseline study (weak
recommendation, low-quality evidence).
Torsades de pointes is a polymorphic ventricular
arrhythmia usually preceded by QTc interval prolongation22,96 that can lead to ventricular fibrillation and
result in sudden death or cardiac arrest.22,84 The risk
of torsades de pointes increases with greater
prolongation of the QTc interval. Torsades de pointes
primarily occurs in patients with QTc intervals
>500 ms, though risk is increased starting around QTc
intervals of 450 ms.22,74,80,88 Although normal QTc
intervals are longer in women than in men, with an
average difference of 10 to 20 ms, it is unclear
whether there are sex differences in risk of torsades
de pointes at increased QTc intervals. Therefore, for
pragmatic purposes, the panel recommends that
clinicians utilize the same QTc interval parameters for
men and women. Risk factors for QTc interval
prolongation include22,26,31,47,93,96
 electrolyte abnormalities such as hypokalemia or hypomagnesemia;
 impaired liver function;
 structural heart disease (such as congenital heart defects or a history of endocarditis or heart failure);
 genetic predisposition such as congenital prolonged
QT syndrome or familial history of prolonged QT syndrome; and
 use of drugs with QTc-prolonging properties
(Table 1).
Methadone use appears to be associated with risk
of prolongation of the QTc interval,26,55,59,66,69,89
presumably because of its potent inhibitory effects on
 go-go-related gene (hERG) cardiac
the human ether a
channel,52,95 and case reports describe torsades de
pointes in patients prescribed methadone.47,57,77 Other
medications associated with QTc interval prolongation
and
torsades
de
pointes
include
various
antiarrhythmics, antipsychotics, citalopram, tricyclic
antidepressants, fluoroquinolones, and cisapride.106
The estimated risk of torsades de pointes varies widely,
ranging from approximately .001% for cisapride to
approximately 8% for quinidine.22 In the case of cisapride, the manufacturer discontinued marketing of the
drug in the United States in 2000, based on 341 cases of
cardiac arrhythmias (including 80 deaths) between
1993 and 1999.98 Although estimates for the degree of
risk associated with drug-induced QTc interval prolongation vary, in patients with long QTsyndrome, a QTc interval >500 ms was associated with an odds ratio for
syncope or sudden death (presumably due to torsades
de pointes) of 4.2 (95% confidence interval [CI] 1.1–
16).8 Because of potential cardiac arrhythmia risk, a baseline ECG is recommended prior to initiating a number of
these medications, with periodic ECG monitoring of patients taking the medications, though evidence showing
the effectiveness of ECG monitoring is lacking.1-3,18,22,23
Similarly, in patients being considered for methadone, a baseline ECG may help clinicians assess for
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Selected Methadone Drug-Drug
Interactions

Table 1.

Table 1.

Continued

ADDITIVE

DRUG

EFFECTS ON
SEDATIVE OR
EFFECTS ON
METHADONE
RESPIRATORY
LEVELS*
QTC INTERVAL DEPRESSANT EFFECTS

Antibiotics
Ciprofloxacin
[
Clarithromycin
[
Erythromycin
[
Itraconazole
[
Ketoconazole
[
Fluconazole
[
Rifampin
Y
Telithromycin
[
Anticonvulsants
Carbamazepine
Y
Phenytoin
Y
Antihistamines
Diphenhydramine
Promethazine
Antipsychotics
Quetiapine
[
Barbiturates
Phenobarbital
Y
Benzodiazepines
Alprazolam
[
Clorazepate
[
Diazepam
[
Estazolam
[
Flurazepam
[
Lorazepam
[
Midazolam
[
Triazolam
[
Zopiclone
[
HIV medications
Abacavir
Y
Nevirapine
Y
Delavirdine
[
Efavirenz
Y
Ritonavir-boosted
Y
lopinavir
Nelfinavir
Y
Amprenavir
Y
Atazanavir
Y
Opioids
Heroin
Y*
Selective serotonin reuptake inhibitors
Fluoxetine
[
Fluvoxamine
[
Nefazodone
[
Paroxetine
[
Sertraline
[
Tricyclic antidepressants
Amitriptyline
Desipramine
Imipramine
Nortriptyline
Protriptyline
Urinary alkalinizers
Bicitra
[
Polycitra
[
[
Verapamil
Other

[
[

[
[
[
[
[
[
[
[
[
[
[
[
[

[
[

[
[
[
[
[

DRUG
Aprepitant
Cimetidine
Cocaine
Disulfiram
Ethanol
Grapefruit juice or
whole fruit
Omeprazole
St. John’s wort

ADDITIVE
EFFECTS ON
SEDATIVE OR
EFFECTS ON
METHADONE
RESPIRATORY
LEVELS*
QTC INTERVAL DEPRESSANT EFFECTS
[
[
Y
[
Y*
[

[
[

[
Y*

NOTE. Most effects are predicted or expected drug interactions; in most cases
direct evidence on changes in methadone levels on and off the second medication are not available. Cytochrome P450 inducers decrease methadone blood
levels; inhibitors increase methadone blood levels. More comprehensive and
periodically updated lists of cytochrome P450 interactions and drugs associated
with QTc prolongation are available at http://medicine.iupui.edu/clinpharm/ddis/
ClinicalTable.aspx and http://QTdrugs.org.
*Data not as strong for interaction.
Leavitt63; McCance-Katz et al,72 Lintzeris et al,65 and Gourevitch et al.40

risk of torsades de pointes, based on the presence and
degree of QTc interval prolongation prior to medication initiation. Accurate estimates on the risk of torsades de pointes or sudden cardiac death are not
available. Recent data suggest that methadone is the
most common drug-related cause of ventricular arrhythmias reported to the FDA.4,51 However, some
studies suggest that in patients on methadone for
opioid addiction, attributable mortality appears
low.4 Although no study has evaluated the effect of
ECG screening and monitoring on clinical outcomes,
and the clinical opinion on the need to obtain ECGs
in patients being considered for methadone varies
markedly, in part because of concerns about delayed
or reduced access to methadone, an ECG is the only
way to detect asymptomatic QTc interval prolongation. Patients with QTc interval prolongation might
benefit from efforts to address causes of QTc interval
prolongation, consideration of alternative opioids or
other interventions, or additional monitoring if prescribed methadone. Although no study has compared
outcomes associated with different ECG strategies in
this setting, the panel recommends that clinicians
routinely obtain an ECG prior to initiation of methadone in patients with known risk factors for QTc interval prolongation, a prior ECG with QTc interval
>450 ms, or a history suggestive of prior ventricular
arrhythmia (such as prior cardiac arrest and unexplained syncope or seizure). Approximately 85% of
cases of cisapride-associated cardiac arrhythmias
occurred in patients with known risk factors for QTc interval prolongation.98 Although data are limited,
studies of methadone-associated torsades de pointes
similarly indicate that a high proportion of patients
had identifiable risk factors.47,58,77,99
For persons not known to be at a higher risk of QTc
interval prolongation, the panel found insufficient evidence to routinely recommend ECG screening.
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However, given that QTc interval prolongation
without arrhythmia is asymptomatic and may not be
associated with recognized risk factors, the panel suggests that clinicians consider obtaining an ECG prior to
initiation of methadone in all patients.
Although there is no evidence to guide recommendations on how recent an ECG should be to guide risk assessments accurately prior to initiation of methadone,
the panel suggests that in patients with risk factors for
QTc interval prolongation that are unchanged, an ECG
within the last 3 months showing no QTc interval prolongation can be used as the baseline study and a repeat
ECG is unnecessary prior to initiating methadone. In patients with no risk factors for QTc interval prolongation,
an ECG within the last year showing no QTc interval prolongation can be used as the baseline study.
The panel found extremely limited evidence to guide
use of screening ECGs prior to initiation of methadone
in children. Although research on long QT syndrome in
families indicates a two- to fourfold increased risk of
cardiac events in children with QTc intervals between
460 and 500 ms,109 the panel found no reported cases
of torsades de pointes in children prescribed methadone, despite relatively common pediatric use in
some hospital settings. Nonetheless, given the potential for increased cardiovascular risk, the panel suggests
that clinicians consider a screening ECG prior to initiating methadone in children with risk factors for prolonged QTc interval, as described above.
 The panel recommends against use of methadone in
patients with a baseline QTc interval >500 ms (strong
recommendation, low-quality evidence).
 The panel recommends that clinicians consider alternate
opioids in patients with a baseline QTc interval $450 ms
but <500 ms. If methadone is considered in a patient with
a baseline QTc interval $450 ms but <500 ms, the clinician
should evaluate for and correct reversible causes of QTc
interval prolongation before initiating methadone
(weak recommendation, low-quality evidence).
 The panel recommends that clinicians consider buprenorphine as a treatment option for patients treated for
opioid addiction who have risk factors for or known
QTc interval prolongation when an agonist/partial
agonist is indicated (weak recommendation,
moderate-quality evidence).
A QTc interval of $500 ms is associated with a substantially increased risk of torsades de pointes.22,74,80,88
In adults, each 10-ms increase in QTc interval is
associated with an approximate 5 to 7% exponential
increase in risk of torsades, so that a patient with a
QTc of 540 ms has a 63 to 97% greater risk than a
patient with a QTc of 440 ms.22 Patients with this degree of QTc interval prolongation prior to starting
methadone may experience further QTc interval prolongation on methadone, placing them at greater
risk.2-14,28,30,31 Therefore, the panel recommends
against use of methadone in adults with a QTc
interval $500 ms at baseline. In such patients, the
panel recommends that clinicians consider alternative
treatments for chronic pain or opioid addiction. For
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patients being managed for chronic pain, a number
of alternative opioids are available. Although QTc
interval prolongation has been reported with
oxycodone, its clinical significance is uncertain.30 Other
opioids have not been associated with QTc interval prolongation in clinical studies. For the treatment of
opioid addiction, buprenorphine has similar efficacy
to moderate doses of methadone but is associated
with less QTc interval prolongation, and is one potential alternative.4,6,28,29,42,56,102 A QTc interval of 450 to
500 ms in adults is also associated with increased risk
of torsades de pointes.47,57,77 Data from general
populations of U.S. adults indicate that less than 5%
of men and women have QTc intervals of
>450 ms.83,111 Although the risk associated with a QTc
interval of 450 to 500 ms is lower than in patients
with QTc intervals of >500 ms, the panel recommends
that clinicians consider alternatives to methadone
because there may be some additional risk. Factors to
consider when deciding whether to initiate
methadone include the degree of QTc interval
prolongation (intervals close to 450 ms are associated
with less risk than intervals closer to 500 ms) and
whether there may be reversible risk factors. In
patients who are prescribed other medications that
prolong QTc interval or who have hypokalemia, the
panel recommends that clinicians stop the other
medications if clinically appropriate and correct
hypokalemia. In such cases, the decision to initiate
methadone would depend in part on whether the
QTc interval improved after such measures. In patients
with nonreversible risk factors such as structural heart
disease or cirrhosis, the use of alternatives to
methadone may be more strongly considered.
However, the efficacy of alternative treatments, as
well as the risks of inadequate or no treatment, must
be considered, especially in treatment of addiction.
Patients with a QTc interval <450 ms at baseline are
not considered to be at increased risk for torsades de
pointes following initiation of methadone, and may
be started on methadone with routine follow-up and
monitoring (see below).
The panel found insufficient evidence to determine
whether QTc thresholds for use of methadone should
differ in children compared with adults. As in adults,
data generally indicate that <5% of children have a
QTc interval >450 ms.44,79,97 In addition, as noted
above, studies of siblings of children with long QT
syndrome found increased risk of cardiovascular
events at QTc intervals of 460 to 500 ms, though
reported cases of torsades de pointes in children
prescribed methadone are rare. Given the potential
for increased risk and the availability of alternative
opioids, the panel suggests that clinicians apply
similar QTc parameters for use of methadone in
children as in adults, until more evidence is available.

Initiation of Methadone
 The panel recommends that clinicians initiate methadone at low doses individualized based on the
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indication for treatment and prior opioid exposure status, titrate doses slowly, and monitor patients for sedation (strong recommendation, moderate-quality
evidence).
Practice Advice: Based on limited research evidence
and clinical experience, the panel suggests the following
parameters:
1) When used to treat opioid addiction, the panel suggests that clinicians start methadone at no more
than 30 to 40 mg once daily. The dose should be
titrated based on objective signs of withdrawal
and self-reported craving and methadone dose
increased by no more than 10 mg/d and no more
frequently than every 3 to 4 days. Methadone
should be withheld if there is evidence of sedation.
2) When used to treat chronic pain in adults on relatively low doses of other opioids (eg, <40–60 mg/
d of morphine or equivalent), the panel suggests
that clinicians start methadone at 2.5 mg tid, with
initial dose increases of no more than 5 mg/d every
5 to 7 days. In children, the recommended starting
dose is 100 mg/kg (maximum 5 mg/dose) every 6 to
8 hours. Methadone should be withheld if there is
evidence of sedation.
3) When used to treat chronic pain and switching to
methadone from higher doses of another opioid,
the panel suggests that clinicians start methadone
therapy at a dose 75 to 90% less than the calculated equianalgesic dose and at no higher than
30 to 40 mg/d, with initial dose increases of no
more than 10 mg/d every 5 to 7 days. Methadone
should be withheld if there is evidence of
sedation.
 The panel recommends that clinicians consider those
patients previously prescribed methadone, but
who have not currently taken opioids for 1 to 2 weeks,
opioid-na€ıve for the purpose of methadone reinitiation (strong recommendation, low-quality evidence).
The panel recommends that clinicians start methadone at low doses and titrate slowly. Evidence to guide
optimal methadone initiation and dose titration strategies is limited. Therefore, suggestions for practice
are based on panel consensus and clinical experience,
and depend on the degree to which a patient is
opioid-experienced, with an overarching goal of
more conservative (lower) initial dosing regimens in order to prioritize patient safety. The rationale for the
panel’s recommendation for careful initiation and
dose titration of methadone is related to the drug’s
long and highly variable half-life.67 Slow titration
may reduce the risk of unintended accumulation that
can occur as the serum concentration slowly rises toward steady state once a dose is selected. It is possible
that rapid titration of the dose to a level that is efficacious for pain could be followed by toxicity over the
course of the next days or even weeks as the concentration rises. In the most serious outcome, this late toxicity
could take the form of respiratory depression and
death. Consistent with this principle is evidence
showing that the period shortly following methadone
initiation appears to be associated with increased risk
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of overdose and other adverse events.27,37,108
Although the half-life of methadone is usually assumed
to be approximately 1 day, and is rarely outside a range
of 15 to 60 hours, in some reports the half-life is as high
as 120 hours.67 By comparison, the plasma half-life of
morphine, hydromorphone, oxycodone, fentanyl, and
codeine range from 2 to 3.5 hours.45 In a patient for
whom the methadone half-life is 60 hours, it would
take almost 12 days on a stable dose of methadone to
approach a steady state (5 half-lives). In addition, patients with a long half-life will have more prolonged
exposure to a given methadone dose, potentially
increasing their risk for adverse events. Without
knowing the half-life in an individual patient, risk can
be minimized only by cautious titration. Clinicians
should be aware that the variable half-life of methadone means that some patients may not reach steady
state (5 half-lives) for over 3 weeks. Therefore, it is critical that clinicians not increase the dose solely based on
preset parameters, but also evaluate patients clinically
and withhold the dose if there is evidence of sedation.
Once the sedation has resolved, methadone may be reinitiated at a lower dose (eg, at least 20% lower than
the dose that caused sedation) and the period between
dose titrations extended.
The panel recommends particular caution when
initiating methadone for pain treatment in patients
with no prior exposure to opioids (‘‘opioid-na€ıve’’). In
this situation, the panel suggests a starting dose of
2.5 mg every 8 hours (7.5 mg/d), with initial dose increases of no more than 5 mg/d every 5 to 7 days, in
accordance with the APS-AAPM Guideline.16 Once
the dose has reached 30 to 40 mg/d and the patient
has shown the ability to tolerate dose increases of
5 mg/d, clinicians may consider larger dose increases
of up to 10 mg/d, though the duration between dose
increases should not be shortened. Evidence indicates
that the risk of overdose is increased at higher doses
of opioids, suggesting that dose increases of methadone above 30 to 40 mg/d should only be done in patients who are clearly benefiting and can be monitored
appropriately.7,24,39
In children, the panel suggests a starting dose of 100
mg/kg (maximum 5 mg/dose initially) every 6 to 8 hours.
Although the World Health Organization suggests a
higher potential starting dose (100–200 mg/kg) with
several initial loading doses (2–3 doses given every
4 hours),105 the panel felt that more cautious initiation
of methadone is warranted in children with chronic
pain, particularly in nonhospital settings. The panel
suggests use of short-acting opioids for breakthrough
pain or if more rapid initial pain control is needed,
rather than loading doses of methadone. As in adults,
the panel recommends dose increases in children no
more frequently than once every 5 to 7 days, based
on the amount of breakthrough pain medications
needed to maintain pain control, by no more than
50% of the current methadone dose.
For patients treated for opioid addiction and
engaged in ongoing opioid use, higher starting doses
and more rapid dose titration may decrease the
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likelihood of withdrawal and increase the likelihood
of treatment success. In such patients, clinicians may
consider starting at higher doses than used in
opioid-na€ıve patients. The panel suggests initiating
methadone at up to 30 to 40 mg once daily and
titrating the dose based on objective signs of withdrawal and self-report of opioid craving, but by no
more than 10 mg/d and with dose increases no
more frequently than every 3 to 4 days.
In patients with chronic pain on higher doses of
alternative opioids, conversion to methadone should
be performed carefully. Proposed equianalgesic dose
ratios for conversion of other opioids (in mg
morphine equivalents) to methadone are variable
and range from 3:1 to 10:1 at lower doses to 8:1 to
20:1 at higher doses.78 In patients on lower doses of
other opioids (eg, <40–60 mg morphine equivalents/
d), the panel suggests starting methadone at doses
similar to those recommended for opioid-na€ıve patients. For patients on higher doses of other opioids,
the panel suggests that clinicians start methadone
at a dose 75 to 90% less than the calculated equianalgesic dose, based on more conservative dosing ratios
(eg, 15:1 to 20:1) and at no higher than 30 to 40 mg/
d.14 Initial dose increases should be no more than
10 mg/d every 5 to 7 days.
The panel recommends that clinicians reinitiate
methadone cautiously in patients who have previously
been prescribed methadone but are currently not taking an opioid. Such patients experience loss of tolerance and are at risk for accidental overdose if
reinitiated at their previously tolerated methadone
dose. Although there is insufficient evidence to determine with precision how quickly tolerance is lost, the
panel suggests that clinicians treat patients not taking
opioids for 1 to 2 weeks as opioid-na€ıve.
Because of its long half-life and variable pharmacokinetics, the panel recommends that methadone not
be used to treat breakthrough pain or as an asneeded medication.16

Follow-Up Electrocardiograms
 The panel recommends that for patients prescribed
methadone, clinicians perform follow-up ECGs based
on baseline ECG findings, methadone dose changes,
and other risk factors for QTc interval prolongation
(strong recommendation, low-quality evidence).
Practice Advice: Based on limited research evidence
and based upon clinical experience, the panel suggests
the following parameters:
1) The panel suggests that for patients with risk factors for QTc interval prolongation, any prior ECG
demonstrating a QTc >450 ms, or a history of syncope, clinicians perform follow-up ECG 2 to 4 weeks
after initiation of methadone therapy and
following significant dose increases.
2) The panel suggests that for all patients, clinicians
perform follow-up ECG when the methadone
dose reaches 30 to 40 mg/d in patients started at
lower doses, and again at 100 mg/d.
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3) The panel suggests that clinicians perform followup ECG for all patients prescribed methadone
with new risk factors for QTc interval prolongation
or signs or symptoms suggesting arrhythmia.
 The panel recommends that clinicians switch
methadone-treated adults with a QTc interval
$500 ms to an alternative opioid or immediately
reduce the methadone dose; in all such cases, the panel
recommends that clinicians evaluate and correct reversible causes of QTc interval prolongation, and repeat the
ECG after the methadone dose has been decreased
(strong recommendation, low-quality evidence).
 The panel recommends that clinicians consider switching methadone-treated adults with a QTc interval
$450 ms but <500 ms to an alternative opioid or
reducing the methadone dose. In patients in whom
there are barriers to switching to alternative opioids,
or who experience decreased treatment effectiveness
with methadone dose reductions, the panel recommends that clinicians discuss with patients the potential
risks of continued methadone. In all cases, the panel recommends that clinicians evaluate and correct reversible
causes of QTc interval prolongation, and repeat the ECG
after the methadone dose has been decreased (strong
recommendation, low-quality evidence).
Follow-up ECGs in patients prescribed methadone
may be useful for identifying QTc interval prolongation that increases the risk for torsades de pointes.
Although there is no evidence to guide optimal strategies for performing follow-up ECGs, the panel suggests that clinicians obtain a follow-up ECG soon
after initiating methadone in patients with QTc interval prolongation at baseline and in patients on
methadone with new risk factors for QTc interval
prolongation of signs or symptoms suggesting ventricular arrhythmia (such as palpitations, presyncope,
or syncope). In addition, some evidence suggests that
the degree of QTc interval prolongation is dose
dependent.13,26,29,53,57,69 Therefore, follow-up ECGs
should also be obtained when methadone daily
doses are increased to certain threshold levels.
Although there are insufficient data to determine
optimal methadone dose threshold levels for ECG
monitoring, the panel suggests 30 to 40 mg/d in patients started at lower doses, and again at 100 mg/d.
The panel suggests that clinicians obtain a follow-up
ECG 2 to 4 weeks after initiation of methadone in patients with a QTc interval >450 ms at baseline, a history
of syncope prior to initiation of methadone, or risk factors for QTc interval prolongation, as well as when patients develop new risk factors for QTc interval
prolongation or report signs or symptoms suggesting
potential arrhythmia. In patients started on low doses
of methadone, the panel also recommends that clinicians perform follow-up ECG when the methadone
dose reaches the thresholds noted previously. The panel
found insufficient evidence to suggest parameters for
follow-up ECGs in patients titrated to higher methadone doses who do not experience QTc interval prolongation at doses of 100 mg/d or lower. However, a high
proportion of case reports of torsades de pointes in
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patients prescribed methadone occurred at high doses
(>200 mg/d), suggesting that additional monitoring at
higher doses (eg, whenever the dose is titrated to 30–
50% higher than the prior dose at which an ECG was obtained) may be warranted.47,57 In patients with QTc
interval prolongation on follow-up ECG, recommendations on use of methadone, consideration of alternatives, and correction of potentially reversible causes
are similar to those described above for QTc interval prolongation on a baseline ECG. In addition, clinicians may
consider lowering the methadone dose with follow-up
to document improvement or normalization of the
QTc interval.28,42,59 For patients treated for opioid
addiction who develop a prolonged QTc interval on
methadone, buprenorphine is a potential alternative.
Buprenorphine has similar efficacy to moderate
doses of methadone for treatment of opioid
addiction,
and
observational
studies
report
normalization of prolonged QTc intervals after
switching
patients
from
methadone
to
buprenorphine.28,42,59 For chronic pain, a number of
opioids are available as alternatives to methadone. A
potential limitation to use of buprenorphine is that it
is a m-opioid partial agonist and may exhibit analgesic
ceiling dose effects at which further dose increases produce no additional effects.100 Clinicians switching patients from methadone to buprenorphine should also
follow recommended methods to avoid precipitated
withdrawal due to initiation of a partial agonist.10

Monitoring for and Management of
Adverse Events
 The panel recommends that patients receiving methadone be monitored for common opioid adverse effects
and toxicities and that adverse effects management be
considered part of routine therapy (strong recommendation, moderate-quality evidence).
In addition to QTc interval prolongation, methadone is associated with other adverse effects typically
associated with opioids, including constipation,
nausea, sedation, respiratory depression, pruritus,
endocrinologic effects, and others. As outlined in the
APS-AAPM guideline on use of opioids for chronic
noncancer pain, the panel recommends that clinicians
anticipate and routinely monitor patients prescribed
methadone for opioid-related adverse effects.16
Adverse effects management, including proactive interventions, should be considered part of routine therapy in all patients prescribed methadone. Clinicians
should routinely consider initiation of a bowel
regimen to prevent or manage opioid-induced constipation. Although evidence is anecdotal, regimens
including increased fluid and fiber intake, stool softeners, and laxatives are often effective. For nausea
and vomiting, a number of antiemetics, in both oral
and rectal forms, are available, though some are associated with QTc interval prolongation (see below).
Patients should be asked about signs or symptoms of
hypogonadism and appropriately tested when present. Clinicians should recognize comorbidities that

may increase the risk of opioid-related adverse effects
such as sleep apnea or other underlying respiratory disease, dementia, or antecedent constipation. Close
monitoring is recommended in such cases.
Clinicians should periodically monitor patients for
the development of substance abuse and other mental
health disorders. Such patients should be managed
appropriately, including referral if necessary and potential discontinuation or restructuring of methadone
therapy. Clinicians should also periodically review state
prescription drug monitoring program data, which are
now widely available, in order to help identify patients
who are obtaining opioids or other controlled substances from other providers, as such behaviors are
associated with increased risk of overdose.
Patients should be counseled on sedation after
opioid initiation and with dose increases, including potential issues related to driving and work and home
safety. However, most epidemiologic studies suggest
that risk of motor vehicle accidents, traffic fatalities,
and citations for impaired driving is not increased in
patients on stable doses of opioids.34,35 In the
absence of signs of symptoms of impairment, the
panel did not identify sufficient evidence to support
restrictions in driving or most work-related activities
in patients maintained on long-term opioid therapy.16
 The panel recommends face-to-face or phone assessment with patients to assess for adverse events within
3 to 5 days after initiating methadone, and within 3 to
5 days after each dose increase (strong recommendation, low-quality evidence).
The risk of methadone-associated mortality is higher
shortly after initiating methadone.9,61,73,107 Although
evidence is sparse on the association between
methadone dose increases and serious adverse events,
a similar association appears plausible. Therefore, the
panel recommends that clinicians reassess patients 3 to
5 days following methadone initiation or after
methadone dose increases, with particular attention
to signs of respiratory depression (such as decreased
respiratory rate or sedation, which may accompany
respiratory depression) and arrhythmia (such as
palpitations). Although there is insufficient evidence
to guide recommendations on optimal methods or
timing for follow-up, the panel recognizes that
follow-up assessments do not necessarily require an office visit with a provider, and may be performed over the
phone by an appropriately trained medical assistant or
nurse or via email for reliable patients.

Urine Drug Testing
 The panel recommends that clinicians obtain urine
drug screens prior to initiating methadone and at regular intervals in patients prescribed methadone for
opioid addiction (strong recommendation, lowquality evidence).
 The panel recommends that patients prescribed methadone for chronic pain who have risk factors for drug
abuse undergo urine drug testing prior to initiating
methadone and at regular intervals thereafter; it
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recommends that clinicians consider urine drug testing
in all patients regardless of assessed risk status (strong
recommendation, low-quality evidence).
One method to monitor patients prescribed opioids
is urine drug testing (UDT). UDT may help identify patients engaging in aberrant drug-related behaviors
and who may benefit from restructuring of their
opioid therapy or treatment of underlying addiction
or opioid misuse. Although no study has evaluated
optimal UDT intervals in patients prescribed methadone or other opioids, the panel suggests that clinicians obtain a baseline UDT, including specific testing
for methadone, in all patients prescribed methadone
for opioid addiction and in all patients prescribed
methadone for chronic pain that have risk factors for
drug abuse. Subsequent UDT should be performed
periodically if justified based on the patients’ assessed
risk for drug abuse or diversion. The APS-AAPM guideline on use of opioids for chronic noncancer pain suggests that clinicians use the risk assessment to help
guide UDT monitoring intervals.16 Patients treated
for opioid addiction are at high risk for opioid abuse
and misuse and generally warrant frequent monitoring. Patients prescribed methadone for chronic
pain who may need more frequent or intense monitoring include those with a prior history of substance
use disorder, patients with an unstable or dysfunctional social environment, and those with comorbid
psychiatric conditions. In patients treated for chronic
pain at low risk for adverse outcomes and on stable
doses of opioids, the APS-AAPM guideline also suggests that clinicians consider UDT monitoring, as evidence indicates that a substantial minority of
patients who engage in aberrant drug-related behaviors do not have identifiable risk factors.48,54 In such
patients, repeat testing every 6 to 12 months may be
sufficient, though clinic follow-up every 3 to 6 months
is generally suggested.

Medication Interactions
 The panel recommends that clinicians use methadone
with care in patients using concomitant medications
with potentially additive side effects or pharmacokinetic
or pharmacodynamic interactions with methadone
(strong recommendation, low-quality evidence).
Evidence on the magnitude of clinical harms associated with the concomitant use of methadone plus potential interacting medications is limited, and most
trials were not designed to evaluate serious harms.
However, several types of drug interactions can increase risk in patients using methadone and therefore
require attention and care in prescribing (Table 1).
These include use of drugs that
 alter methadone absorption, metabolism, and/or
excretion, thereby changing methadone blood
levels;
 have additive or synergistic sedative or respiratory
suppressant effects; and/or
 prolong QTc intervals.
Like other opioids, methadone is primarily
metabolized in the liver and gastrointestinal tract25 by
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cytochrome P450 (CYP) enzymes including CYP2B6,
CYP3A4, CYP 2C19, CYD2D6, and CYP1A2.62,104 Many
other medications can affect the metabolism of
methadone and other opioids because they are CYP
inhibitors (leading to increased opioid levels)63 or
CYP inducers (leading to decreased opioid levels).36
CYP inhibitors may increase risk for sedation and respiratory depression at a specific opioid dose, and CYP inducers may reduce effectiveness of methadone at a
specific dose or precipitate withdrawal.
In addition, like other opioids, methadone has
sedating and respiratory depressant effects that may
be augmented by use of medications and drugs (such
as alcohol) with similar effects. In particular, a high proportion of cases of overdoses involving methadone
occurred in patients with benzodiazepines in their system at the time of death.12,37,90,94,103 The panel
suggests
that
clinicians
generally
avoid
benzodiazepines in patients prescribed methadone
because of the possible association with increased
overdose risk. However, in stable patients on longterm low doses of a benzodiazepine plus methadone,
the panel found insufficient evidence for or against
routine discontinuation of the benzodiazepine,
though a careful consideration of potential risks relative to benefits is warranted.
Finally, care is needed when combining methadone
with other drugs that may prolong QTc intervals. In
spontaneously reported cases of methadoneassociated arrhythmia, antiretroviral drugs for human
immunodeficiency virus were the most common coadministered drugs.51 The ECG should be carefully monitored and doses of methadone and/or other drugs
adjusted to keep the QTc within a safe range, as discussed elsewhere in this Guideline.
The panel recommends that clinicians review
patient medications prior to initiation of methadone
and consider discontinuation or dose reduction of
medications with potential interactions or additive
side effects (Table 1). If methadone is initiated, the
panel recommends close monitoring following methadone initiation. In patients on methadone, clinicians should review new medications for potential
interactions before starting them, monitor for interactions if they are used, and make appropriate methadone dose changes when a CYP inducer or inhibitor
is discontinued or when the dose is adjusted. For
example, discontinuation of a CYP inducer in a patient prescribed methadone could result in high
methadone levels, potentially increasing the risk for
overdose.

Methadone Use in Pregnancy
 The panel recommends monitoring of neonates
born to mothers receiving methadone for neonatal
abstinence syndrome and treatment for neonatal
abstinence syndrome when present (strong recommendation, moderate-quality evidence).
Neonatal abstinence syndrome occurs in threequarters or more of infants exposed to methadone
prenatally.20,43,49,50,64,75,81,82,86,87,110
Evidence
on
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comparative risk of neonatal abstinence syndrome
associated with different opioids is limited but may be
higher with methadone than buprenorphine.33,46
Although most studies have evaluated the incidence of
neonatal abstinence syndrome following maternal use
of methadone for treatment of opioid addiction,
methadone has also become frequently used for
treatment of chronic pain in women of childbearing age.
Opioid agonist treatment with methadone is the current standard of care for opioid addiction during pregnancy in order to improve both maternal and fetal
outcomes.19 Detailed guidance regarding management of addiction during pregnancy is beyond the
scope of this Guideline but is available from the American Congress of Obstetrics and Gynecology.19 For
women with chronic pain, clinicians should weigh the
benefits and harms of methadone and other opioids
when considering its use during pregnancy and inform
women of the potential risks to the newborn, as well as
the risk of opioid withdrawal with discontinuation of
methadone during pregnancy. The panel recommends
monitoring of all newborns born to mothers receiving
methadone for neonatal abstinence syndrome and
provision of appropriate treatments when it occurs.

Conclusions
Use of methadone for treatment of chronic pain has
increased dramatically, in part because of its lower cost
relative to other long-acting opioids, despite limited evidence of efficacy for treatment of chronic pain.15 Methadone maintenance therapy is a mainstay of treatment
for opioid addiction and is associated with reduced heroin and illicit drug use, greater retention in therapy, and
a trend toward reduced mortality risk.71 At the same
time, overdoses associated with methadone use have
increased dramatically, methadone is associated with
unique pharmacologic properties that complicate its
use, and alternatives to methadone are available for
treatment of both chronic pain and opioid addiction. After a review of the available evidence, an expert panel
convened by APS, CPDD, and HRS concludes that measures can be taken to promote safer use of methadone.
The recommendations presented in this Guideline are
based on the underlying assumption that safe use of
methadone requires clinical skills and knowledge in

assessing and balancing potential risks against potential
benefits of methadone, monitoring and management of
risks, with the core goal of promoting patient safety and
preventing avoidable harms, including serious events
such as accidental overdose and fatal arrhythmia. Unlike
other Guidelines,60,70,92 which primarily focused on
prevention of arrhythmia, the recommendations in this
Guideline also address aspects of patient risk
assessment, education and counseling, dose initiation
and titration, monitoring, and medication interactions
that are directly or indirectly related to risk of
respiratory depression, thought to be the primary cause
of methadone-associated deaths.
Although these guidelines are based on a systematic
review of the evidence on methadone safety, the panel
identified numerous research gaps. In fact, the panel
only rated 4 recommendations as supported by even
moderate-quality evidence. Nonetheless, the panel
came to near-unanimous consensus on almost all of its
recommendations, including the need to educate and
counsel patients on methadone safety, use of ECG to
identify persons at greater risk for methadoneassociated arrhythmia, use of alternative opioids in patients at high risk of complications related to QTc interval
prolongation, careful dose initiation and titration of
methadone, and diligent monitoring and follow-up.
The panel acknowledges that implementation of these
guidelines has important implications for resource utilization and cost. However, at this time there is insufficient evidence to reliably estimate or model the costs associated
with implementation. Given the number of potentially
preventable deaths associated with methadone and the
availability of alternative treatments, the panel
concluded that enhanced efforts to mitigate risks of methadone are justified despite the limited evidence with
which to estimate their potential impact. Research is urgently needed to confirm the effectiveness and costeffectiveness of the recommendations in this Guideline.
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American Pain Society Clinical Practice Guidelines Grading System*
STRENGTH OF RECOMMENDATION

QUALITY OF EVIDENCE
High
Moderate
Low
Insufficient evidence to determine net benefits or harms

BENEFITS DO OR DO NOT
CLEARLY OUTWEIGH RISKS

BENEFITS AND RISKS AND BURDENS
ARE FINELY BALANCED

Strong
Strong
Strong
No recommendation

Weak
Weak
Weak
No recommendation

*From the system developed by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) work group and adapted by the American Pain
Society.

